1.
Chinese Journal of Biologicals
; (12): 105-111+118, 2023.
Artículo
en Chino
| WPRIM
| ID: wpr-965587
RESUMEN
@#Abstract:Programmed death receptor⁃ 1(PD⁃1)belongs to the family of immunoglobulin B7⁃CD28,which plays an important role in regulating immune response in human body. Since the first PD⁃1/PD⁃ligand 1(PD⁃L1)monoclonal antibody was approved for marketing in China in 2018,the value of PD⁃1/PD⁃L1 immunotherapy in oncotherapy has attracted wide attention. Based on the introduction of the action mechanism of PD⁃1/PD⁃L1 mAbs,this paper reviews the application progress of 8 on ⁃ market PD ⁃ 1/PD ⁃ L1 mAbs in China in oncotherapy from the perspectives of approved indications,clinical trials,usage and dosage,and adverse reactions,in order to provide reference for the rational appli⁃ cation of PD⁃1/PD⁃L1 monoclonal antibodies in clinic.